These results establish the feasibility of conducting studies correlating expression levels of FMR4, FMR5, and FMR6 with clinical outcomes in FXS and FXTAS patients. This evidence concerns the gene FMR1-AS1 and fragile X-associated tremor/ataxia syndrome.